Agnuside

Research use only, not for human use.

Agnuside inhibits COX-2 (IC50: 0.026 mg/ml) but exhibits less than 10% inhibition of COX-1 at this concentration. It also inhibits 46.3 66.8 and 82.1% of P-glycoprotein (P-gp) ATPase activity at concentrations of 5 25 and 100 μM respectively.

Agnuside inhibits COX-2 (IC50: 0.026 mg/ml) but exhibits less than 10% inhibition of COX-1 at this concentration. It also inhibits 46.3 66.8 and 82.1% of P-glycoprotein (P-gp) ATPase activity at concentrations of 5 25 and 100 μM respectively.

——

Animal Model:Balb/C female mice model Dosage:30 mg/kg, 60 mg/kg Administration:Oral gavage (p.o.); Single dose;Result:Decreased the expression of LC3B and increased the expression of Beclin1/p62 (LC3B and Beclin1/p62 are autophagy markers).Decreased the levels of IgE and IL-4/ IL-10 in a dose-dependent manner.( IgE and IL-4/ IL-10 are allergic inflammatory mediators).Animal Model:KAO rat model Dosage:6.25 mg Monosodium iodoacetate (MIA): 1 mg Administration:Oral gavage (p.o.); Single dose Result: Alleviated the degree of local hypoxia in the synovial tissue of rats and significantly reduced the level of pro-fibrotic substances in the synovial tissue.Inhibited the accumulation of HIF-1α and activation of NLRP3 inflammasome.

chasteberry oil

Chromatin/Epigenetic

COX

COX-2| P-gp?(P-glycoprotein)

——

——

11027-63-7

466.44

C22H26O11

>98% (HPLC)

DMSO: 10 mg/mL

OC[C@H]1O[C@@H](O[C@@H]2OC=C[C@H]3[C@H](O)C=C(COC(=O)c4ccc(O)cc4)[C@@H]23)[C@H](O)[C@@H](O)[C@@H]1O

[(1S4aR5S7aS)-5-Hydroxy-1-[(2S3R4S5S6R)-345-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-14a57a-tetrahydrocyclopenta[c]pyran-7-yl]methyl 4-hydroxybenzoate

(-20℃)

With Ice Pack

≥ 2 years